摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Methoxy-3-nitrobenzylamin | 21078-49-9

中文名称
——
中文别名
——
英文名称
4-Methoxy-3-nitrobenzylamin
英文别名
(4-Methoxy-3-nitrophenyl)methanamine
4-Methoxy-3-nitrobenzylamin化学式
CAS
21078-49-9
化学式
C8H10N2O3
mdl
MFCD06213179
分子量
182.179
InChiKey
IEHOMRHZTHOKRM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    81.1
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and Structure–Activity Relationships of New Quinolone-Type Molecules against Trypanosoma brucei
    摘要:
    Human African trypanosomiasis (HAT) or sleeping sickness is caused by two subspecies of Trypanosoma brucei, Trypanosoma brucei gambiense, and Trypanosoma brucei rhodesiense and is one of Africa's old plagues. It causes a huge number of infections and cases of death per year because, apart from limited access to health services, only inefficient chemotherapy is available. Since it was reported that quinolones such as ciprofloxacin show antitrypanosomal activity, a novel quinolone-type library was synthesized and tested. The biological evaluation illustrated that 4-quinolones with a benzylamide function in position 3 and cyclic or acyclic amines in position 7 exhibit high antitrypanosomal activity. Structure-activity relationships (SAR) are established to identify essential structural elements. This analysis led to lead structure 29, which exhibits promising in vitro activity against T. b. brucei (IC50 = 47 nM) and T. b. rhodesiense (IC50 = 9 nM) combined with low cytotoxicity against macrophages J774.1. Screening for morphological changes of trypanosomes treated with compounds 19 and 29 suggested differences in the morphology of mitochondria of treated cells compared to those of untreated cells. Segregation of the kinetoplast is hampered in trypanosomes treated with these compounds; however, topoisomerase II is probably not the main drug target.
    DOI:
    10.1021/jm101439s
  • 作为产物:
    描述:
    4-甲氧基苄胺甲基叔丁基醚硝酸硫酸 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 1.0h, 以89%的产率得到4-Methoxy-3-nitrobenzylamin
    参考文献:
    名称:
    通过硝酸盐单硝化芳族化合物
    摘要:
    带有碱性氮原子的芳族化合物可以转化为相应的硝酸盐。化合物的单硝化反应可以通过将盐的二氯甲烷溶液添加到硫酸中,或将乙酰氯(或三氟乙酸酐)添加到盐的二氯甲烷溶液中来进行。除其他优点外,该协议还提供了最方便,最可靠的方式来防止硝化过度/欠燃,尤其适用于规模放大。
    DOI:
    10.1016/j.tetlet.2007.10.027
点击查看最新优质反应信息

文献信息

  • Cyclic compounds
    申请人:——
    公开号:US20040142930A1
    公开(公告)日:2004-07-22
    1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, 1 wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.
    化合物的公式(I)或其药理学上可接受的盐,其中X为═CH—或═N—,Y为—NH—,—NR4—,—S—,—O—,—CH═N—,—N═CH—,—N═N—,—CH═CH—等,R1为较低的烷氧基,氨基,含N原子的杂环环,或者由含N原子的杂环环取代的羟基(每个都可以取代),R2为较低的烷基氨基基,可以由芳基取代,较低的烷氧基,可以由芳基取代,由含N原子的芳基取代的较低的烷氧基,R3为芳基,含N原子的杂环环,较低的烷基,较低的烷氧基,环状较低的烷氧基,由含N原子的杂环环取代的羟基,或者氨基(每个都可以取代),R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性,因此,可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
  • Mono-nitration of aromatic compounds via nitrate salts
    申请人:Cedilote Miall
    公开号:US20070255057A1
    公开(公告)日:2007-11-01
    A method of nitrating a compound selected from the group consisting of is provided.
    提供了一种从所选化合物中硝化的方法。
  • Mono-nitration of aromatic compounds
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2327677A1
    公开(公告)日:2011-06-01
    A process to produce a compound of the formula is provided.
    一种生产式化合物的工艺 的工艺。
  • US7273868B2
    申请人:——
    公开号:US7273868B2
    公开(公告)日:2007-09-25
  • US7220736B2
    申请人:——
    公开号:US7220736B2
    公开(公告)日:2007-05-22
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐